Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biovie Inc (BIVI)

Biovie Inc (BIVI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,140
  • Shares Outstanding, K 7,540
  • Annual Sales, $ 0 K
  • Annual Income, $ -17,540 K
  • EBIT $ -19 M
  • EBITDA $ -19 M
  • 60-Month Beta 0.53
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.48

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.81
  • Number of Estimates 1
  • High Estimate -0.81
  • Low Estimate -0.81
  • Prior Year -4.60
  • Growth Rate Est. (year over year) +82.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2500 +26.00%
on 11/21/25
1.7000 -7.35%
on 12/04/25
+0.0250 (+1.61%)
since 11/05/25
3-Month
1.2500 +26.00%
on 11/21/25
2.0732 -24.03%
on 10/15/25
-0.1650 (-9.48%)
since 09/05/25
52-Week
1.2500 +26.00%
on 11/21/25
30.9000 -94.90%
on 12/06/24
-27.9250 (-94.66%)
since 12/05/24

Most Recent Stories

More News
Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on December 9

CARSON CITY, Nev., Nov. 19, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and...

BIVI : 1.5572 (-3.28%)
Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

BIVI : 1.5572 (-3.28%)
Nexalin Technology and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FLORIDA / ACCESS Newswire / October 17, 2025 / RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and BioVie, Inc. (Nasdaq:BIVI) on the RedChip Small Stocks, Big...

NXL : 0.9900 (+2.80%)
BIVI : 1.5572 (-3.28%)
BioVie to Host Live Investor Webinar and Q&A on Oct. 8

CARSON CITY, Nev., Sept. 26, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and...

BIVI : 1.5572 (-3.28%)
BioVie and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FLORIDA / ACCESS Newswire / September 26, 2025 / RedChip Companies will air interviews with BioVie Inc. (NASDAQ:BIVI) and FibroBiologics, Inc. (Nasdaq:FBLG) on the RedChip Small Stocks, Big Money™...

BIVI : 1.5572 (-3.28%)
FBLG : 0.2510 (-3.46%)
BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes

CARSON CITY, Nev., Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and...

BIVI : 1.5572 (-3.28%)
BioVie Inc. Announces Closing of $12 Million Public Offering

CARSON CITY, Nev., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI, BIVIW), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic...

BIVI : 1.5572 (-3.28%)
New to The Street to Air Show #683 on Bloomberg, Featuring BioVie, FLOKI, PetVivo, and NRx Pharmaceuticals

NEW YORK CITY, NY / ACCESS Newswire / August 9, 2025 / New to The Street, one of the nation's longest-running business television brands, will broadcast Show #683 on Bloomberg today at 6:30 PM EST. This...

PETV : 1.0950 (-2.23%)
BIVI : 1.5572 (-3.28%)
NRXP : 2.36 (-3.18%)
BioVie Inc. Announces Pricing of $12 Million Public Offering

CARSON CITY, Nev., Aug. 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI, BIVIW), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic...

BIVI : 1.5572 (-3.28%)
BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology

CARSON CITY, Nev., July 24, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of...

BIVI : 1.5572 (-3.28%)

Business Summary

BioVie Inc. engages in developing drug therapies for liver disease. The company's product candidate includes BIV201, which are in clinical stage. BioVie Inc. is based in SANTA MONICA, CA.

See More

Key Turning Points

3rd Resistance Point 1.8267
2nd Resistance Point 1.7633
1st Resistance Point 1.6867
Last Price 1.5572
1st Support Level 1.5467
2nd Support Level 1.4833
3rd Support Level 1.4067

See More

52-Week High 30.9000
Fibonacci 61.8% 19.5737
Fibonacci 50% 16.0750
Fibonacci 38.2% 12.5763
Last Price 1.5572
52-Week Low 1.2500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar